TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27856288
Drug: aCT1 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: aCT1 gel formulation plus conventional standard of care protocols
Study: 25588457
Drug: Single hyaluronate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single hyaluronate injection (HI group)
Study: 22359979
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once a week or Ibandronate 50 mg once a month
Study: 15641878
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risperidone and paroxetine
Study: 10944645
Drug: Individualized counseling
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized counseling aimed at limiting fat intake to 30% to 35% of daily energy, with a saturated:monounsaturated:polyunsaturated fatty acid ratio of 1:1:1 and cholesterol intake of less than 200 mg/d (n = 540)
Study: 8628561
Drug: 0.1% DfNa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% DfNa eye drops three times daily
Study: 1481685
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAAs) supplementation (7.5-12 g) during exercise
Study: 31047687
Drug: Intravenous tissue‐plasminogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue‐plasminogen activator (IV tPA)
Study: 31047687
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment decisions (IV tPA and MT)
Study: 25808292
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of BDP pMDI and FF pMDI
Study: 21725513
Drug: Dopamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine with saline solution before endoscopic biliary drainage (n=64)
Study: 21725513
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution alone before endoscopic biliary drainage (n=38)
Study: 21725513
Drug: Additional dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dopamine administration during the postdrainage phase (n=31)
Study: 21725513
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional dopamine administration during the postdrainage phase (n=33)
Study: 23086020
Drug: Guanfacine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (1 mg)
Study: 18025315
Drug: Spray (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray (n = 63)
Study: 12423708
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day) added to ongoing statin therapy
Study: 10890228
Drug: Pentaglobin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (5 ml/kg body weight intravenously each day for 5 days)
Study: 10890228
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% glucose solution with 1% human albumin, 5 ml/kg body weight intravenously each day for 5 days)
Study: 8688309
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH), 50 IU/kg (n = 101)
Study: 1707570
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with nitrosomethylurea, vincristine, and peplomycin
Study: 1707570
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with nitrosomethylurea, vincristine, and bleomycetin
Study: 1707570
Drug: Single-agent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent treatment with dacarbazine
Study: 7049819
Drug: Dilazep 300
Normalized name: dilazep
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep 300 mg/die
Study: 7049819
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/die
Study: 19834467
Drug: Successful aging
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful aging (SA) intervention involving weekly educational workshops
Study: 18453642
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention (Taiji exercises, cognitive-behavioral therapies, support group)
Study: 12877571
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg (formulation A)
Study: 12877571
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg (formulation B)
Study: 12877571
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg (formulation A)
Study: 12877571
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation 500 mg (formulation C)
Study: 12877571
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation 750 mg (formulation B)
Study: 8889283
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg moclobemide b.i.d. for 16 days
Study: 8889283
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg selegiline b.i.d. for 16 days
Study: 8889283
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of moclobemide and selegiline
Study: 1905394
Drug: Lactobacillus GG‐fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG‐fermented milk product, 125 g (10(10‐11) colony‐forming units) twice daily (group 1)
Study: 1905394
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG freeze‐dried powder, one dose (10(10‐11) colony‐forming units) twice daily (group 2)
Study: 1905394
Drug: Placebo, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, a pasteurized yogurt, 125 g twice daily (group 3)
Study: 6359379
Drug: Pneumovax (14-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumovax (14-valent pneumococcal vaccine)
Study: 8083452
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (4 mg) four times a day for 10 weeks
Study: 17466698
Drug: 17-alpha-hydroxyprogesterone caproate
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha-hydroxyprogesterone caproate (17P) 341 mg intramuscularly, twice each week until gestational week 36
Study: 11583724
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (17 beta E(2)‐D and CEE‐N)
Study: 3521487
Drug: 8% arildone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% arildone cream
Study: 29552942
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin acetate (LA) (n = 40)
Study: 29552942
Drug: 1.88 mg
Normalized name: glycine 1.88 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.88 mg leuprorelin acetate (LA) (n = 40)
Study: 29552942
Drug: Mirena implantation
Normalized name: Mirena Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirena implantation after treatment with 3.75 mg LA (n = 40)
Study: 29552942
Drug: Mirena implantation
Normalized name: Mirena Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirena implantation after treatment with 1.88 mg LA (n = 20)
Study: 29552942
Drug: San-Jie-Zhen-Tong capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: San-Jie-Zhen-Tong capsules alone (n = 20)
Study: 17134892
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 3 years
Study: 17134892
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 3 years (in node-positive subgroup)
Study: 17134892
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 3 years (in ER and PR positive subgroup)
Study: 15915033
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural analgesia (4 days of continuous infusion of 4 ml/h bupivacaine, 0.125%, and 50 mug/ml morphine)
Study: 12495789
Drug: Ketamine psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine psychotherapy (KPT) with a high dose of ketamine (2.0 mg/kg im)
Study: 12495789
Drug: Ketamine psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine psychotherapy (KPT) with a low dose of ketamine (0.2 mg/kg im)
Study: 7644901
Drug: Enriched commands
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched commands (e.g., 'wave your hands as a conductor')
Study: 7644901
Drug: Basic commands
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic commands (e.g., 'wave your hands')
Study: 2671059
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of brotizolam
Study: 2671059
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of flurazepam
Study: 30771737
Drug: Trimetazidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (35 mg bid)
Study: 28292385
Drug: Mitomycin-C injection
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C injection 1 month before surgery
Study: 28292385
Drug: Mitomycin-C injection
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C injection 24 hours before surgery
Study: 20704642
Drug: 1% hydroalcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hydroalcoholic testosterone gel (50 mg/5 g gel), increased to 10 mg if clinically unsatisfactory
Study: 15490268
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily for 360 days
Study: 11309547
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg once daily, 400 mg on day 1)
Study: 11309547
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg once daily)
Study: 9603272
Drug: Women's sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women's sensitive approach to drug-user treatment
Study: 9603272
Drug: Treatment discharge
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discharge status
Study: 26515712
Drug: Engaged in
Normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engaged in therapy (attended ≥ 6 sessions)
Study: 23053464
Drug: M4 (magnesium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: M4 (magnesium, 4 g)
Study: 9492915
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate at a single dose rate of 10 mg/kg body weight
Study: 10450449
Drug: Albendazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (single 400 mg dose)
Study: 3555385
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 25 mg every two weeks
Study: 3555385
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 5 mg every two weeks
Study: 3555385
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate with dosage adjustment up to 10 mg
Study: 3555385
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 25 mg
Study: 3555385
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 5 mg
Study: 28043438
Drug: Baroreflex Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex Activation Therapy (BAT) plus medical therapy
Study: 25904747
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir treatment
Study: 23685637
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (0.5 μg/kg/min)
Study: 16314619
Drug: Efaproxiral at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efaproxiral at 75 or 100 mg/kg
Study: 10984077
Drug: Insulin (Actrapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (Actrapid MC Novo, 0.1 IU/kg, i.v.)
Study: 10984077
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (50 g and 100 g)
Study: 9010703
Drug: Pranlukast (112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (112.5 to 675 mg, oral, every 12 h)
Study: 9010703
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of pranlukast
Study: 9010703
Drug: Evening doses
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening doses of pranlukast
Study: 1476921
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) administered in fasting conditions
Study: 1476921
Drug: 8-methoxypsoralen (8-MOP)
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen (8-MOP) administered after food ingestion (low-fat or fat-rich breakfast)
Study: 16174272
Drug: Listerine mouthwash
Normalized name: Listerine Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine mouthwash (10 ml, rinsed twice a day for 60 seconds)
Study: 16174272
Drug: 0.1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% chlorhexidine (CHX) mouthwash (10 ml, rinsed twice a day for 60 seconds)
Study: 16174272
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (10 ml, rinsed twice a day for 60 seconds)
Study: 8667921
Drug: Longer maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer maintenance chemotherapy (2 years)
Study: 8667921
Drug: Intensive reinduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive reinduction chemotherapy during maintenance
Study: 29265496
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication + proton pump inhibitor for 7 weeks
Study: 29265496
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor for 8 weeks (non-eradication group)
Study: 24337358
Drug: Biological condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological condition (N=176)
Study: 22596166
Drug: Study therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study therapy (intensive or conventional methotrexate-based treatment)
Study: 20634720
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg moxonidine (MOX) daily
Study: 15897698
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 10 days
Study: 11916760
Drug: CSII plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII plus 200 mg alpha-tocopherol/d
Study: 9840721
Drug: Etoposide (100mg/m2/1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100mg/m2/1 h) administered immediately before and at the end (24 h) of MTX treatment
Study: 9840721
Drug: Etoposide (100mg/m2/1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100mg/m2/1 h) administered at 24 and 48 h after starting MTX infusion
Study: 9840721
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (5g/m2/24 h)
Study: 7500751
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive (30 micrograms ethinyloestradiol)
Study: 7500751
Drug: Low-dose OCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OCs with a third-generation progestagen
Study: 2225484
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg p.o. at -60 min)
Study: 495512
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mg oral dose of prazosin (Group A, no. = 7)
Study: 495512
Drug: Oral prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prazosin, 2 mg every 8 hours for 24 hours (Group B, no. = 7)
Study: 28340281
Drug: FND with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FND with concurrent rituximab
Study: 22029223
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of quetiapine fumarate 25 mg film-coated tablet
Study: 22029223
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of quetiapine fumarate 25 mg film-coated tablet
Study: 17917907
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activities (Control)
Study: 1149490
Drug: co-trimoxazole (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-trimoxazole (480 mg trimethoprim and 2,400 mg sulphamethoxazole daily)
Study: 1149490
Drug: tetracycline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetracycline (2 g daily)
Study: 28177187
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg (T+C)
Study: 26298786
Drug: JZP-110 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4)
Study: 20508536
Drug: High-protein recovery
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein recovery diet (1.4/0.7/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Study: 20508536
Drug: Isocaloric control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric control condition (2.1/0.1/0.26 g·kg(‐1)·h(‐1) of CHO/protein/fat)
Study: 18444947
Drug: Heparin-coated autotransfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated autotransfusion system
Study: 18444947
Drug: Non-heparin-coated autotransfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-coated autotransfusion system
Study: 12906366
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg capsule in the evening)
Study: 10784307
Drug: PGI2 5
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 5 microg x ml(‐1)
Study: 10784307
Drug: PGI2 10
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 10 microg x ml(‐1)
Study: 9038439
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine (single dose 2 h before surgery)
Study: 9038439
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine (every 12 h for 2 days before surgery)
Study: 1889841
Drug: Renin inhibitor
Normalized name: Renin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin inhibitor Ro 42-5892 (0.3 mg/kg injected at 30 minutes, followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes)
Study: 1889841
Drug: Ang II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang II infusion (2 ng/kg/min from 0 to 60 minutes and 4 ng/kg/min from 60 to 120 minutes)
Study: 1889841
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of Ang II and Ro 42-5892 (same doses as above)
Study: 6133645
Drug: Beta-blocking drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking drugs (specific drugs not mentioned)
Study: 20558918
Drug: Intravenous cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cephazolin (CEZ) at 2 g/day for 5 days
Study: 20558918
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (LVFX) at 300 mg/day for 5 days
Study: 7561823
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (anticholinergic agents)
Study: 1973718
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 g every 24 hours for 5 to 7 days
Study: 1973718
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 12 hours for 5 to 7 days
Study: 1973718
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 24 hours for 5 to 7 days
Study: 1973718
Drug: Short-course treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course treatment regimens (any of the above)
Study: 17356507
Drug: mepivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine + ropivacaine 40 mg
Study: 17356507
Drug: mepivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine + ropivacaine 25 mg
Study: 17356507
Drug: mepivacaine 1.5%
Normalized name: mepivacaine 1.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 1.5% (300 mg)
Study: 16356430
Drug: Initial L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial L-thyroxine dose of 50 mug
Study: 16356430
Drug: Initial L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial L-thyroxine doses (50 mug, 37.5 mug)